Compare Cytokinetics Inc (CYTK) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Cytokinetics Inc trades at $62.42 (market cap $8.62B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.76 (market cap $3.14B). The key difference: Cytokinetics Inc is far larger — about 2.7× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Cytokinetics Inc is more actively traded (2,594,626 versus 1,461,349). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| CYTK | SPHD | |
|---|---|---|
Market Cap | $8.62B | $3.14B |
Volume | 2,594,626 | 1,461,349 |
Sector | Health | — |
52-Week High | $87.26 | $53.55 |
52-Week Low | $54.76 | $46.96 |
Typical Hold Time | 19 Days | 125 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
SPHD trades at $48.72 with a 1.1% daily gain, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF's monthly dividend structure provides consistent income, though recent analysis highlights underperformance compared to peers like SCHD over the past decade. Key support sits at $47 with resistance at $49.
The outlook remains cautious given bearish technical signals and competitive pressure from higher-performing dividend ETFs. While monthly dividends appeal to income-focused investors, SPHD's lack of quality screening exposes it to yield traps. Near-term performance depends on market volatility and dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
